AI assistant
RELMADA THERAPEUTICS, INC. — Director's Dealing 2022
May 27, 2022
34465_dirs_2022-05-26_40788966-9823-4353-8c7b-5d408af4d7c5.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: RELMADA THERAPEUTICS, INC. (RLMD)
CIK: 0001553643
Period of Report: 2021-12-17
Reporting Person: CASAMENTO CHARLES J (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-05-25 | Stock Option (right to buy) | $19.03 | A | 91235 | Acquired | 2031-12-17 | Common Stock (91235) | Direct |
Footnotes
F1: The option grant was approved by the Board of Directors of the Company on December 17, 2021, subject to shareholder approval of an amendment to the Company's 2021 Equity Incentive Plan (the "Plan") increasing the number of shares of Common Stock available for the grant of awards under the Plan in an amount sufficient to cover this option grant. Shareholder approval was received for such amendment on May 25, 2022, at the 2022 Annual Meeting of the Company's shareholders.
F2: The option vests in 16 equal quarterly installments, at 6.25% per quarter, commencing on March 17, 2022.